Image: StatnewsAnalysis: Trump's secretive pharma deals may undermine drug-pricing policy
• The White House signed secretive agreements with 26 drugmakers that may exempt various medicines from mandatory price reductions in Medicare. • A new analysis indicates these deals could drastically reduce the projected savings from the "most-favored nation" pricing policy, which aims to align U.S. drug costs with lower prices paid abroad. • These exemptions could limit the government's ability to lower prescription costs for millions of Medicare beneficiaries.
statnews.com




